Los Angeles, CANCT06437574Now EnrollingIRB Ready

Prostate Cancer Clinical Trial in Los Angeles, CA

Access cutting-edge prostate cancer treatment through this phase 2 clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by Cedars-Sinai Medical Center

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions…

Expert Care in Los Angeles

Access prostate cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related prostate cancer treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this prostate cancer clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Prostate Cancer Study in Los Angeles

To test the hypothesis that intensive cholesterol lowering (iCL) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase II trial in prostate cancer patients who are in active surveillance and undergoing a planned surveillance biopsy in 3-6 months. Eligible patients will initiate iCL with Vytorin®(group 1, 2, and 3), an FDA-approved combination of ezetimibe and simvastatin used to lower atherogenic low density lipoprotein cholesterol (LDL-C) or Ezetimibe (group 4). Starting dose will be determined by current statin use and LDL-C levels. Dose modifications of VYTORIN will be employed with the goal of achieving LDL-C \<70 mg/dl. Dose adjustment is not allowed for ezetimibe.

Sponsor: Cedars-Sinai Medical Center

Who Can Participate

Inclusion Criteria

Provision of signed and dated informed consent form.
Stated willingness to comply with all study procedures and availability for the duration of the study.
At least one Atherosclerotic Cardiovascular Disease (ASCVD) risk factor, such as:
≥ 50 years of age
Hypertension
Hypercholesterolemia
Current or former smoker
First-degree family history of any cardiovascular heart disease
On hypertension treatment, statin, and/or aspirin therapy
Patients with clinically localized prostate cancer. That is Low or intermediate risk prostate cancer defined as:
Pre-operative PSA (Prostate Specific Antigen) ≤ 20.0 ng/ml
Clinical stage T1c or cT2
Gleason score 3+3 or 3+4 or 4+3
Patients on AS with plans for surveillance biopsy
No previous treatment for prostate cancer with radiotherapy, chemotherapy, or hormonal therapy
Ability to take oral medication and be willing to adhere to once daily, oral Vytorin or ezetimibe.
Agree to avoid consumption of grapefruit and grapefruit juice ≥ one quart per day throughout study duration.

Exclusion Criteria

Current use of medications contraindicated for use with a statin such as strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, and nefazodone).
Current use of medications contraindicated for use with ezetimibe (i.e., gemfibrozil, cyclosporine, or danazol).
History of allergic or severe reaction to a either study agent.
History of moderate or severe myalgia with statin use.
Acute liver failure or decompensated cirrhosis
Already on maximum VYTORIN dose (10/80)
Already on medication(s) known to interact with Vytorin or Ezetimibe that may prevent protocol-based escalation of cholesterol-lowering therapy from pre-enrollment baseline.
Already on a PCSK9 inhibitor

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT06437574) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Prostate Cancer Treatment Options in Los Angeles, CA

If you're searching for prostate cancer treatment options in Los Angeles, CA, this clinical trial (NCT06437574) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all prostate cancer clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Los Angeles, CA

See all prostate cancer clinical trials recruiting in Los Angeles — not just this study.

Browse Prostate Cancer Trials in Los Angeles →

Browse More Trials by Condition

Prostate Cancer TrialsAll Conditions →

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA